Global Colorectal Cancer Drugs Market 2015-2019

大腸癌治療薬の世界市場2015-2019

◆タイトル:Global Colorectal Cancer Drugs Market 2015-2019
◆商品コード:IRTNTR6118
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年6月17日
◆ページ数:109
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、大腸癌治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、大腸癌治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Colorectal Cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.
Technavio’s analysts forecast the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer.

Based on the type of molecule, the market is grouped into two categories:
• Biologics
• Small molecules

Based on the route of administration, the market is grouped into two categories:
• Oral
• Parenteral

This report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions:
• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population
• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.

Technavio’s report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Amgen
• Bayer
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Serono

[Other Prominent Vendors]
• Accord Healthcare
• Advenchen Laboratories
• Aeterna Zentaris
• AstraZeneca
• Bavarian Nordic
• Biothera
• Boehringer Ingelheim
• Daiichi Sankyo
• Debiopharm
• Eisai
• Eli Lilly
• Immodulon Therapeutics
• Mologen
• Mylan
• Nektar Therapeutics
• Oncothyreon
• Otsuka Pharmaceutical
• Precision Biologics
• Sun Pharmaceutical
• Symphogen
• Taiho
• Takeda
• Teva
• ThromboGenics
• Xbiotech
• Yakult Honsha

[Market Driver]
• Increase in population of patients
• For a full, detailed list, view our report

[Market Challenge]
• Loss of patent exclusivity
• For a full, detailed list, view our report

[Market Trend]
• Dominance of biologics
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.5 Staging
06.5.1 Staging: Colon Cancer
06.5.2 Staging: Rectal Cancer
06.6 Management
06.7 Economic Burden

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.2.1 Colorectal Cancer Drugs Market in US
07.2.2 Colorectal Cancer Drugs Market in Germany
07.2.3 Colorectal Cancer Drugs Market in Spain
07.2.4 Colorectal Cancer Drugs Market in Japan
07.2.5 Colorectal Cancer Drugs Market in China
07.3 Five Forces Analysis

08.Market Segmentation by Type of Molecules
08.1 Small molecules
08.2 Biologics

09.Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral

10.Geographical Segmentation
10.1 Colorectal Cancer Drugs Market in Americas
10.1.1 Market Size and Forecast
10.2 Colorectal Cancer Drugs Market in EMEA
10.2.1 Market Size and Forecast
10.3 Colorectal Cancer Drugs Market in APAC
10.3.1 Market Size and Forecast

11.Key Leading Countries
11.1 US
11.2 Japan
11.3 Germany
11.4 Spain
11.5 China

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Competitive Assessment of Top Drugs for Colorectal Cancer
19.2.2 F. Hoffmann-La Roche
19.2.3 Merck Serono
19.2.4 Bristol-Myers Squibb
19.2.5 Amgen
19.2.6 Sanofi
19.2.7 Bayer
19.3 Other and Future Prominent Vendors

20.Key Takeaways

21.Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Bayer
21.2.1 Key facts
21.2.2 Business overview
21.2.3 Business segmentation by revenue 2014
21.2.4 Business segmentation by revenue 2013 and 2014
21.2.5 Geographical segmentation by revenue 2014
21.2.6 Business strategy
21.2.7 Recent developments
21.2.8 SWOT analysis
21.3 Bristol-Myers Squibb Co.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Product Offerings
21.3.4 Revenue by Geography
21.3.5 Business Strategy
21.3.6 Key Information
21.3.7 SWOT Analysis
21.4 F. Hoffmann-La Roche Ltd.
21.4.1 Key Facts
21.4.2 Business Overview
21.4.3 Business Segmentation
21.4.4 Business Segmentation by Revenue 2012 and 2013
21.4.5 Sales by Geography
21.4.6 Business Strategy
21.4.7 Key Information
21.4.8 SWOT Analysis
21.5 Merck Serono
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Geographical Segmentation by Revenue 2013
21.5.4 Business Strategy
21.5.5 Recent Developments
21.5.6 SWOT Analysis
21.6 Sanofi SA
21.6.1 Key Facts
21.6.2 Business Description
21.6.3 Business Segmentation
21.6.4 Revenue by Business Segmentation
21.6.5 Revenue Comparison 2012 and 2013
21.6.6 Sales by Geography
21.6.7 Business Strategy
21.6.8 Key Developments
21.6.9 SWOT Analysis

22.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Drivers and Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 3: Diagnosis of Colorectal Cancer
Exhibit 4: Management of Colorectal Cancer
Exhibit 5: A Snapshot of the Economic Burden of the Global Colorectal Cancer Drugs Market
Exhibit 6: Snapshot of the Global Colorectal Cancer Drugs Market
Exhibit 7: Global Colorectal Cancer Drugs Market 2014-2019 ($ millions)
Exhibit 8: Colorectal Cancer Drugs Market in US 2014-2019 ($ millions)
Exhibit 9: Colorectal Cancer Drugs Market in Germany 2014-2019 ($ millions)
Exhibit 10: Colorectal Cancer Drugs Market in Spain 2014-2019 ($ millions)
Exhibit 11: Colorectal Cancer Drugs Market in Japan 2014-2019 ($ millions)
Exhibit 12: Colorectal Cancer Drugs Market in China 2014-2019 ($ millions)
Exhibit 13: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules
Exhibit 14: Segmentation of Global Colorectal Cancer Drugs Market by Type of Molecules, 2014
Exhibit 15: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration
Exhibit 16: Segmentation of Global Colorectal Cancer Drugs Market by Route of Administration, 2014
Exhibit 17: Global Colorectal Cancer Drugs Market by Geographical Segmentation 2014
Exhibit 18: Colorectal Cancer Drugs Market in Americas 2014-2019 ($ millions)
Exhibit 19: Colorectal Cancer Drugs Market in EMEA 2014-2019 ($ millions)
Exhibit 20: Colorectal Cancer Drugs Market in APAC 2014-2019 ($ millions)
Exhibit 21:
Exhibit 22: Drivers of the Global Colorectal Cancer Drugs Market
Exhibit 23: Challenges of the Global Colorectal Cancer Drugs Market
Exhibit 24: Trends of the Global Colorectal Cancer Drugs Market
Exhibit 25: YoY Growth Rate of the Major Colorectal Cancer Drugs 2010-2014 ($ millions)
Exhibit 26: F. Hoffmann-La Roche: Product Portfolio
Exhibit 27: Avastin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 28: Avastin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 29: YoY Revenues and Growth Rate of Avastin in the US 2010-2014 ($ millions)
Exhibit 30: YoY Revenues and Growth Rate of Avastin in Europe 2010-2014 ($ millions)
Exhibit 31: YoY Revenues and Growth Rate of Avastin in Japan 2010-2014 ($ millions)
Exhibit 32: YoY International Revenues and Growth Rate of Avastin 2010-2014 (Except US, Europe, Japan) ($ millions)
Exhibit 33: Xeloda: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 34: Xeloda: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 35: YoY Revenues and Growth Rate of Xeloda in the US ($ millions)
Exhibit 36: YoY Revenues and Growth Rate of Xeloda in Europe 2010-2014 ($ millions)
Exhibit 37: YoY Revenues and Growth Rate of Xeloda in Japan 2010-2014 ($ millions)
Exhibit 38: YoY International Revenues and Growth Rate of Xeloda (Except US, Europe, Japan) ($ millions)
Exhibit 39: Merck Serono: Product Portfolio
Exhibit 40: Erbitux: Revenue and YoY Growth Rate except US and Canada 2010-2014 ($ millions)
Exhibit 41: Erbitux: Region-wise Revenues 2012-2014 ($ millions)
Exhibit 42: Erbitux: Revenue and YoY Growth Rate in Europe 2012-2014 ($ millions)
Exhibit 43: Erbitux: Revenue and YoY Growth Rate in Emerging Markets 2012-2014 ($ millions)
Exhibit 44: Erbitux: Revenue and YoY Growth Rate in ROW 2012-2014 ($ millions)
Exhibit 45: Bristol-Myers Squibb: Product Portfolio
Exhibit 46: Erbitux: Revenue and YoY Growth Rate in US and Canada 2010-2014 ($ millions)
Exhibit 47: Amgen: Product Portfolio
Exhibit 50: Vectibix: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 51: Vectibix: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 52: Sanofi: Product Portfolio
Exhibit 53: Eloxatin: Global Revenue and YoY Growth Rate 2010-2014 ($ millions)
Exhibit 54: Eloxatin: Region-wise Revenues 2010-2014 ($ millions)
Exhibit 55: YoY Revenues and Growth Rate of Eloxatin in the US ($ millions)
Exhibit 56: YoY Revenues and Growth Rate of Eloxatin in Europe ($ millions)
Exhibit 57: YoY Revenues and Growth Rate of Eloxatin in Emerging Markets ($ millions)
Exhibit 58: YoY Revenues and Growth Rate of Eloxatin in ROW 2010-2014 ($ millions)
Exhibit 59: Zaltrap: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 60: Zaltrap: Region-wise Revenue 2013-2014 ($ millions)
Exhibit 61: Bayer: Product Portfolio
Exhibit 62: Stivarga: Global Revenue and YoY Growth Rate 2012-2014 ($ millions)
Exhibit 63: Key Takeaways: Global Colorectal Cancer Drugs Market 2015-2019
Exhibit 64: Amgen: Business Segmentation by Revenue 2013
Exhibit 65: Amgen: Product Portfolio by Revenue 2013
Exhibit 66: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 67: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 68: Bayer: Business segmentation by revenue 2014
Exhibit 69: Bayer: Business segmentation by revenue 2013 and 2014 (US$ billion)
Exhibit 70: Bayer: Geographical segmentation by revenue 2014
Exhibit 71: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 72: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 73: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 74: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 75: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 76: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 77: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 78: Sanofi SA: Business Segmentation
Exhibit 79: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 80: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 81: Sanofi SA: Sales Revenue by Geographical Segmentation 2013



【掲載企業】

Amgen, Bayer, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck Serono, Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, Bavarian Nordic, Biothera, Boehringer Ingelheim, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, Immodulon Therapeutics, Mologen, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, Yakult Honsha

【資料のキーワード】

大腸癌治療薬、投与経路、医薬品、製薬、がん治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[大腸癌治療薬の世界市場2015-2019] (Global Colorectal Cancer Drugs Market 2015-2019 / IRTNTR6118)販売に関する免責事項
[大腸癌治療薬の世界市場2015-2019] (Global Colorectal Cancer Drugs Market 2015-2019 / IRTNTR6118)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆